Andreas Wagner Sells 11,602 Shares of Alignment Healthcare (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC) insider Andreas Wagner sold 11,602 shares of the stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $18.22, for a total transaction of $211,388.44. Following the transaction, the insider directly owned 148,628 shares of the company’s stock, valued at $2,708,002.16. This trade represents a 7.24% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alignment Healthcare Price Performance

Shares of ALHC stock traded down $0.03 during trading hours on Thursday, hitting $18.16. The stock had a trading volume of 3,987,587 shares, compared to its average volume of 2,967,147. Alignment Healthcare, Inc. has a one year low of $11.63 and a one year high of $23.87. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.71 and a quick ratio of 1.71. The stock’s 50-day moving average price is $20.57 and its two-hundred day moving average price is $18.78. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -1,814.19, a PEG ratio of 2.62 and a beta of 1.18.

Alignment Healthcare (NASDAQ:ALHC) last posted its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The firm’s revenue for the quarter was up 44.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.16) earnings per share. Equities analysts forecast that Alignment Healthcare, Inc. will post -0.69 EPS for the current year.

Hedge Funds Weigh In On Alignment Healthcare

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Alignment Healthcare by 10.9% during the 4th quarter. Vanguard Group Inc. now owns 15,492,802 shares of the company’s stock valued at $305,983,000 after purchasing an additional 1,524,218 shares during the last quarter. Wellington Management Group LLP lifted its position in Alignment Healthcare by 26.9% in the fourth quarter. Wellington Management Group LLP now owns 14,070,893 shares of the company’s stock worth $277,900,000 after buying an additional 2,981,166 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Alignment Healthcare by 0.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 12,643,784 shares of the company’s stock worth $249,715,000 after buying an additional 79,268 shares during the last quarter. Invesco Ltd. boosted its stake in Alignment Healthcare by 38.9% during the fourth quarter. Invesco Ltd. now owns 6,202,592 shares of the company’s stock worth $122,501,000 after buying an additional 1,735,962 shares during the period. Finally, Hood River Capital Management LLC boosted its stake in Alignment Healthcare by 6.0% during the second quarter. Hood River Capital Management LLC now owns 5,517,336 shares of the company’s stock worth $77,243,000 after buying an additional 311,424 shares during the period. Hedge funds and other institutional investors own 86.19% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ALHC shares. Piper Sandler raised their target price on shares of Alignment Healthcare from $20.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday, January 6th. JPMorgan Chase & Co. upped their price target on shares of Alignment Healthcare from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. KeyCorp reiterated an “overweight” rating and set a $28.00 price objective on shares of Alignment Healthcare in a research report on Thursday, January 22nd. TD Cowen lifted their price objective on shares of Alignment Healthcare from $18.50 to $25.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alignment Healthcare presently has an average rating of “Moderate Buy” and a consensus price target of $24.56.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.